The Structure of the SlrP-hTrx1 Complex Sheds Light on the Autoinhibition Mechanism of the Type-III Secretion System Effectors of the NEL Family by Zouhir, Samira et al.
  
 
1
The Structure of the SlrP-hTrx1 Complex Sheds Light on the 
Autoinhibition Mechanism of the Type-III Secretion System Effectors 
of the NEL Family 
 
Samira Zouhir*, Joaquín Bernal-Bayard†, Mar Cordero-Alba†, Elena Cardenal-Muñoz†, Beatriz 
Guimaraes‡, Noureddine Lazar§, Francisco Ramos-Morales† & Sylvie Nessler*§ 
 
* Laboratoire d’Enzymologie et Biochimie Structurales (LEBS), CNRS UPR 3082, 91198 Gif sur Yvette, 
France 
†  Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Apartado 1095,41080 Sevilla, 
Spain 
‡ Synchrotron SOLEIL, 91192 Gif sur Yvette, France 
§ Institut de Biochimie et Biophysique Moléculaire et Cellulaire (IBBMC) University Paris-Sud 11, UMR 
8619, 91405 Orsay, France 
 
 
Corresponding authors: Sylvie Nessler, Institut de Biochimie et Biophysique Moléculaire et Cellulaire 
(IBBMC) University Paris-Sud 11, UMR 8619, 91405 Orsay, France, Tel.: (+33)169157966; Fax: 
(+33)169853715; E-mail: sylvie.nessler@u-psud.fr; Francisco Ramos-Morales, Departamento de 
Genética, Facultad de Biología, Universidad de Sevilla, Avda. Reina Mercedes 6, 41012 Sevilla, Spain, 
Tel.: (+34)954557107; Fax: (+34)954557104; E-mail: framos@us.es 
 
SZ and JBB contributed equally to this work 
 
Present addresses:   
SZ: Laboratório Nacional de Biociências (LNBio), CNPEM, Campinas, Brazil  
JBB: Département de Microbiologie, Institut Pasteur, 75724 Paris cedex 15, France 
 
Short title: Structural analysis of the SlrP/Trx1 complex 
 
Keywords: Salmonella infection; Effector-host protein interaction; Crystal structure; LRR domain; 
Ubiquitination; Novel bacterial E3 ligase 
Biochemical Journal Immediate Publication. Published on 03 Sep 2014 as manuscript BJ20140587
TH
IS
 IS
 N
O
T 
TH
E 
VE
RS
IO
N 
O
F 
RE
CO
RD
 - 
se
e 
do
i:1
0.
10
42
/B
J2
01
40
58
7
Ac
ce
pte
d M
a
us
cri
pt
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2014 The Authors Journal compilation © 2014 Biochemical Society
  
 
2
Abstract 
 
Salmonella infections are a leading cause of bacterial foodborne illness in the United States and the 
European Union. Antimicrobial therapy is often administered to treat the infection but increasing isolates 
are being detected that demonstrate resistance to multiple antibiotics. Salmonella enterica contains two 
virulence related type-III secretion systems (T3SS):  one promotes invasion of the intestine and the other 
one mediates systemic disease. Both of them secrete the SlrP protein acting as E3 ubiquitin ligase in 
human host cells where it targets thioredoxin-1 (Trx1). SlrP belongs to the NEL family of bacterial E3 
ubiquitin ligases that have been observed in two distinct autoinhibitory conformations. We solved the 3D 
structure of the SlrP/Trx1 complex and determined the Trx1 ubiquitination site. The description of the 
substrate-binding mode sheds light on the first step of the activation mechanism of SlrP. Comparison with 
the available structural data of other NEL effectors allowed us to gain new insights into their 
autoinhibitory mechanism. We propose a molecular mechanism for the regulation of SlrP in which 
structural constraints sequestrating the NEL domain would be sequentially released. This work thus 
constitutes a new milestone in the understanding of how these T3SS effectors influence pathogen 
virulence. It also provides the fundamental basis for future development of new antimicrobials. 
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3
INTRODUCTION 
 
Infectious diseases are a major concern of human health and the steady rise of antibiotic resistance 
urges for new strategies to reduce bacterial infections. While traditional antibiotics kill or slow bacterial 
growth, an important emerging strategy to combat pathogens seeks to block the ability of bacteria to harm 
the host by inhibiting bacterial virulence factors. Many pathogenic bacteria are able to manipulate the 
cellular integrity of host cells by secreting proteins in the extracellular environment or inside host cells. In 
Gram-negative pathogens, the translocated proteins, named effectors, are directly delivered into the host-
cell cytoplasm through the type-III secretion system (T3SS), which displays a needle-like structure [1]. 
The T3SS offers an interest as target for the design of new antibiotics [2]. However, another therapeutic 
approach consists in targeting the secreted effectors that, once delivered by the T3SS, play critical roles in 
manipulating the host cell to allow for bacterial invasion, intracellular survival and proliferation [3,4]. 
The nature of the effectors is very variable [5,6] and they utilize three main strategies to modify host cell 
function [7]: they directly bind to, covalently modify, or mimic endogenous host cell proteins. 
Although ubiquitin (Ub) is absent from bacteria, some species secrete effectors displaying E3 
ubiquitin ligase activity, which are able to subvert the ubiquitination pathway of the human host cell [8,9]. 
Ubiquitination consists in the covalent attachment of one or more ubiquitin molecules to lysine residues 
of substrate proteins. This post-translational modification constitutes an attractive target for a wide range 
of pathogens because it regulates many pathways in eukaryotic cells such as protein degradation by the 
26S proteasome, DNA repair or activation of protein kinases [10]. Ubiquitination involves a cascade of 
three enzymes [11]. First, the ubiquitin-activating enzyme (E1) activates the ubiquitin molecule through 
an ATP-dependent reaction to create a thioester bond between the E1 catalytic cysteine and the 
carboxylate of the ubiquitin C-terminal glycine. In the second step, the activated ubiquitin is transferred 
by a transthiolation reaction from E1 to a member of the ubiquitin-conjugating enzyme (E2) family. 
Finally, in the presence of a ubiquitin–protein ligase (E3), which binds to specific substrates, ubiquitin is 
conjugated to the target protein by the formation of an isopeptide bond between the carboxyl terminus of 
ubiquitin and the -amino group of a lysine residue of the target protein [11]. E3 ligases determine the 
substrate specificity of ubiquitination and have been classified into two main classes, the HECT and 
RING finger families [12]. The more prevalent RING-type E3 ligases bring together an E2-Ub conjugate 
and a substrate protein, and in most cases, ubiquitin is transferred directly from the E2 to the substrate. By 
contrast, HECT-type E3 ligases are directly involved in the catalytic process: ubiquitin is transferred from 
the E2 enzyme to the catalytic cysteine of the HECT domain, and then to a lysine residue of the target 
[13]. Most known bacterial E3 ligases do not share sequence similarity with eukaryotic E3 ligases [14]. 
They display however structural similarity with the RING-type [15] or HECT-type enzymes [16].  
Recently, a new family of bacterial E3 ligases has been discovered among T3SS effectors of a subset 
of pathogenic bacteria [17]. They are characterized by the presence of a N-terminal leucine-rich repeat 
(LRR) domain involved in protein/protein interactions [18] and a C-terminal catalytic domain displaying 
an -helical fold completely distinct from either the RING or HECT domains [19]. This catalytic domain 
was named NEL for “Novel E3 Ligase”. The presence of the N-terminal substrate-binding domain and the 
requirement for a catalytic cysteine are reminiscent of the mechanism of HECT-type E3-ligases [20]. 
Similarly, the catalytic cysteine located within a conserved CXD motif of the NEL domain acts as a 
nucleophile to catalyze ubiquitin transfer through a transthiolation reaction.  
Comparison of the structures of the full-length effectors IpaH3 from Shigella flexneri (PDB ID 3CVR) 
[21] and SspH2 from Salmonella enterica serovar Typhimurium (PDB ID 3G06) [22] revealed that the 
LRR and NEL domains, which are linked by a flexible loop, display drastic distinct relative orientations. 
SspH2 is in a closed autoinhibitory conformation burying the catalytic cysteine in the domain interface. 
The NEL domain is orientated toward the concave face of the banana shaped LRR domain. A bridging 
interaction is observed between the catalytic and αG-αH loops of the NEL domain and the N-terminus of 
the linker region. In the IpaH3 structure the αG-αH loop interacts with the convex side of the LRR 
domain while the catalytic loop is exposed to the solvent. This open conformation was first interpreted as 
the active state of the LRR-NEL effectors [14]. However, a recent mutational analysis [23] demonstrated 
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that both conformations protect the LRR-NEL effectors from autoubiquitination and it was proposed that 
these two autoinhibition modes could be released upon substrate binding [23]. 
In a previous study [24] we showed that one of the members of this LRR-NEL family of T3SS 
effectors, the Salmonella secreted protein SlrP, specifically recognizes the reduced form of human 
thioredoxin-1 (Trx1). Ubiquitination of this essential redox protein resulted in an increased susceptibility 
of the host cells to death. In the present work, we solved the crystal structure of the SlrP/Trx1 complex 
and identified the Trx1 ubiquitination site. The comparison of these new results with the available data 
concerning other LRR-NEL proteins finally allowed us to assess the role of substrate binding in the 
autoinhibition mechanism of these T3SS effectors. 
 
EXPERIMENTAL  
 
Bacterial and yeast strains and culture 
Bacterial strains used in this study are Escherichia coli BL21(DE3) (Stratagene), M15 (Qiagen), 
DH5 [25] and XL1-Blue [26], and Salmonella enterica serovar Typhimurium 14028. Culture medium 
for bacteria was Luria-Bertani (LB) broth. Antibiotics were used at the following final concentrations: 
ampicillin, 100 μg/ml; kanamycin, 50 μg/ml; tetracycline, 20 μg/ml. Saccharomyces cerevisiae strains 
used are Y2HGold (Clontech) and Y187 [27]. Culture media for yeast were YPD and yeast drop out 
lacking the appropriate supplements: tryptophan to select for the presence of pGBKT7 derivatives, 
leucine for pGADT7 derivatives, histidine and adenine to check interactions. Solid media contained agar 
at 1.5 % final concentration. 
 
Plasmids and mutagenesis 
To obtain the plasmid to generate 6His recombinant proteins, DNA from strain 14028 was used as a 
template for PCR amplification. The amplified fragments were digested with BamHI and SalI and ligated 
with BamHI/SalI-digested pQE30 (Qiagen). Plasmid pREP4 (Qiagen), that constitutively expresses the 
lac repressor protein encoded by the lacI gene, was used to regulate expression of 6His recombinant 
proteins. Derivatives of pGEX-4T-1 and pGEX-4T-3 (GE Healthcare) were used for production of GST 
fusion proteins. To generate point mutations in slrP and trx1, the previously described plasmids [24] 
pIZ1635 (pGBKT7-SlrP), pIZ1710 (pGADT7-Trx1) and pIZ1712 (pGEX-4T-1-Trx1) were used as 
templates. Amplification reactions were carried out in a T100 thermal cycler (BioRad) using KAPA HiFi 
DNA polymerase (Kapa Biosystems) and the primers listed in Table S1. The PCR cycling parameters 
were set up as following: (i) initial denaturation, 3 min at 95°C; (ii) 17 cycles of denaturation (98°C, 20 s), 
annealing (62°C, 15 s), and extension (72°C, 30s/kb); (iii) final extension (72ºC, 5 min). Products were 
digested with 1 µl of DpnI (10 U/µl) for 1 h at 37°C and E. coli DH5α was transformed with these 
digested plasmids. All PCR constructs were confirmed by DNA sequencing using an automated DNA 
sequencer (Stab Vida, Oeiras, Portugal). 
 
Yeast two-hybrid methods 
Plasmids were introduced into Saccharomyces cerevisiae strains Y2HGold or Y187 using the lithium 
acetate transformation procedure, as previously described [28]. Yeast transformed with the appropriate 
plasmids were mixed onto YPD plates and incubated at 30ºC overnight. The mating mixtures were plated 
in yeast drop out medium lacking tryptophan and leucine. Plates were incubated at 30ºC for 3 days and 
then colonies were patched on the same medium and replica-plated on medium lacking tryptophan, 
leucine, histidine and adenine, to check for the expression of the HIS3 and ADE2 reporters. 
 
Protein preparation 
The human trx1 gene and the slrP gene fragments from Salmonella enterica serovar Typhimurium 
corresponding to residues 1 to 140 and 140 to 765 were cloned into pQE30 plasmids and expressed with 
an N-terminal 6His-tag as recombinant proteins in E. coli M15/pREP4 strain. The oligonucleotides used 
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for cloning are shown in Table S1. The same production and purification protocols were used for all 
proteins, except that 5mM β-mercapto-ethanol was added in all Trx buffers to stabilize the reduced form 
of the protein that has been shown to interact with SlrP [24]. Bacteria were grown in LB medium 
containing 100 µg/ml of ampicillin and 50µg/ml of kanamycin at 37°C. At mid-exponential growth phase 
(OD600 = 0.6-0.8), the temperature was decreased to 30°C and 1 mM of IPTG was added to induce 
expression and incubation was pursued for 4h. The cells were harvested by centrifugation at 5000 rpm for 
20 min at 4°C. The cell pellet was resuspended in lysis buffer (20 mM Tris-HCl, pH 7.5, 300 mM NaCl 
and 10 mM imidazole, +/- 5mM β-mercapto-ethanol). A commercial mixture of protease inhibitors 
(Sigma) was added to the suspension and lysis was performed by sonication. The cell lysate was 
centrifuged at 15000 g for 30 min at 4°C and the supernatant filtered (0.20 µm) before loading onto a 
Ni2+-NTA column equilibrated with lysis buffer. After extensive washing the 6His-tagged protein was 
eluted with 300 mM imidazole in lysis buffer. The eluted fraction was filtered (0.20 µm) and injected 
onto a size exclusion column (Superdex S200 26/60 for SlrP and Superdex S75 26/60 for Trx1) 
equilibrated in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM β-mercapto-ethanol. The purification was 
performed at 5°C on an HPLC ÄKTA Purifier (GE Pharmacia). The purified proteins were concentrated 
by ultrafiltration (Vivaspin 30 kDa and 5kDa for SlrP and Trx1, respectively) and stored aliquoted at -
20°C.  
Selenomethionine-labeled SlrP was produced from E. coli strain M15/pREP4/pIZ1784 grown 
overnight at 28°C in the presence of 100 µg/ml of ampicilin and 25 µg/ml of kanamicin in M9 minimal 
medium supplemented with 100 µg/ml of Lys, Thr and Phe, and 50 µg/ml of Leu, Ile, Val and Met. At 
mid-exponential growth phase (OD600=0.6), the cells were harvested by centrifugation at 5000 rpm for 10 
min at room temperature and resuspended in fresh M9 mediun supplemented as before except for 
methionine that was replaced by 50µg/ml of selenomethionine. After incubating 30 min at 37°C, 
expression was induced with 1mM of IPTG for 4h at 37°C. The purification protocol was unchanged. 
Expression of the GST fusion proteins was induced by the addition of 1 mM isopropyl β-D-
thiogalactoside to E. coli BL21(DE3) bacteria containing pGEX-4T-1, pGEX-4T-3 or their derivatives, 
and the fusion proteins were isolated from bacterial lysates by affinity chromatography with glutathione-
agarose beads (Sigma). For lysis, bacteria were sonicated in Nonidet P-40 buffer (10 mM Tris-HCl, pH 
7.4, 150 mM NaCl, 10% glycerol, 1% Nonidet P-40, 1% aprotinin, 1 mM phenylmethylsulfonyl fluoride, 
1 μg/ml pepstatin, and 1 μg/ml leupeptin). 
 
Size-exclusion chromatography – Multi-angle laser light scattering measurements 
The chromatographic analyses of SlrP and Trx proteins were performed using the SEC–TDA equipment 
by Viscotek (Malvern, France). Protein samples of 100 µl were loaded at a flow rate of 0.5 ml/min onto a 
Agilent Bio Sec-3 column and eluted in 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM β-mercapto-ethanol. 
Elution was followed by a UV-Visible spectrophotometer, a differential refractometer, a 7° Low Angle 
Light Scattering detector, a 90° Right Angle Light Scattering detector and a differential pressure 
viscometer. The instrument was calibrated using bovine serum (Sigma–Aldrich). The OmniSEC software 
program was used for the acquisition and analysis of the data. 
 
Pull-down experiments 
Bacterial extracts from M15/pREP4 strains expressing 6His proteins were incubated at 4ºC for 3 h 
with GST or GST-Trx proteins bound to glutathione-coupled agarose beads. The precipitates were 
washed six times in Nonidet P-40 buffer followed by SDS-PAGE. The gel was blotted onto a 
nitrocellulose membrane and probed with monoclonal anti-His antibody (1:3000; GE Healthcare). Goat 
anti-mouse horseradish peroxidase-conjugated antibodies (BioRad) were used as secondary antibodies. 
Detection was via chemiluminescence procedures (Pierce). 
 
Crystal structure determination 
Co-crystallization conditions were determined at 18°C with various concentrations and ratio of 
purified SlrP and Trx1 proteins. Commercial crystallization kits were screened using a nanodrop 
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6
crystallization Cartesian robot (Genomics Solutions, UK). Co-crystals were obtained in both Qiagen kit 
solutions MB Class II n°63 (0.1M MgCl2, 0.1M NaCl, 0.1M HEPES, pH7.5, 12% PEG 4000) and PEG-II 
n°94 (0.2M Mg Acetate, 10% PEG 8000). The co-crystals were manually reproduced and optimized at 
18°C using the hanging drop method in a crystallization solution containing 0.1M MgCl2, 0.2M NaCl, 
0.1M HEPES, pH 7.8 and 15% PEG 4000, with a SlrP/Trx1 molar ratio of 1:2 by mixing 216µM SlrP 
with 430µM Trx1. The crystals were flash frozen in liquid nitrogen using the crystallization solution 
supplemented with 30% ethylene glycol as cryoprotectant. A native diffraction data set was collected at 
100 K on beamline ID29 at synchrotron ESRF (Grenoble, France). The crystals diffracted up to 3.3Å 
resolution in space group P212121. The diffraction data were processed using the XDS package [29]. 
Molecular replacement performed using the program PHASER [30] failed to solve the crystallographic 
phase problem by using either of the LRR and NEL domains from the available structures of IpaH3 (PDB 
ID 3CVR) [21] or SspH2 (PDB ID 3G06) [22]. 
New co-crystals of the SlrP/Trx1 complex were obtained using a seleno-methionine-labelled form of 
SlrP. SeMet-SlrP at 274µM was co-crystallized with 609µM Trx1 in a crystallization solution containing 
18% PEG 8000, 0.2M Mg Acetate and 0.1M Tris-HCl, pH 8.8. The crystals were flash frozen in liquid 
nitrogen using the crystallization solution supplemented with 30% glycerol as cryoprotectant. A data set 
was collected at the selenium edge on beamline Proxima 1 of the synchrotron SOLEIL (Gif-sur-Yvette, 
France). The energy of the beamline was set to correspond to the maximum of the anomalous factor f’’ as 
determined by a fluorescence scan. The crystals diffracted up to 3.6Å and were isomorphous to the native 
ones. The sub-structure determination was performed with the program SHELXD [31] and initial phasing 
was performed with the program PHASER [30]. Electron density modification was carried out using 
PARROT [32]. Subsequent model building was done manually with COOT [33]. Non-crystallographic 
symmetry was applied in the first steps of refinement performed against the SAD data set using BUSTER 
[34]. Final refinement was performed against the native data set using PHENIX [35]. The data processing 
and refinement statistics are given in Table 1.  
 
Ubiquitination assays  
Single (K8A, K36A and K94A) and the triple (K8A/K36A/K94A) derivative mutant versions of Trx1 
were constructed and tested in ubiquitination assays following the protocol previously published [24] with 
some modifications. Briefly, ubiquitination reactions were performed in a 20-μl mixture containing buffer 
A (25 mM Tris-HCl, pH 7.5, 50 mM NaCl, 5 mM ATP, 10 mM MgCl2, 0.1 mM DTT), 1 μg of HA-
tagged ubiquitin (Boston Biochem), 0.25 μg of human recombinant E1 (Boston Biochem), and 1 μg of E2 
(human recombinant UbcH5b from Boston Biochem) in the presence of 0.5 μg of GST-SlrP and/or GST-
Trx1 (wild type or mutants). Reactions were incubated at 37ºC for 1 h and stopped by addition of an equal 
volume of Laemmli sample buffer containing 100 mM DTT. Reaction mixtures were immunoprecipitated 
with agarose conjugate anti-Trx polyclonal antibody (Santa Cruz Biotechnology) and then subjected to 
immunoblot analysis. 
 
Structure analysis  
Structure comparisons and calculations of rmsd distances have been performed by the protein structure 
comparison service Fold at the European Bioinformatics Institute [36]. Contact and interface calculations 
have been performed by the Protein Interfaces, Surfaces and Assemblies service (PISA) at the European 
Bioinformatics Institute [37]. Multiple sequence alignment was performed using ClustalW [38] and 
secondary structure elements were shown at the top of the alignment using ESPript [39].  The model of 
the apo dimer of SlrP was prepared using COOT. Figures of 3D structures were generated using PYMOL 
(DeLano Scientific LLC). The final model of the native SlrP/Trx1 complex was evaluated using the 
COOT validation tools, and the MolProbity software [40] before deposition in the Protein Data Bank 
(Berman et al, 2000) under ID code 4PUF. 
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RESULTS 
 
Crystal structure of the SlrP/Trx1 complex  
LRR-NEL effectors present at their N-terminus a third domain that has been shown to direct their 
translocation [41] and localization in the host cell [42]. There is a substantial amount of evidence 
suggesting that secretion signals of T3SS effectors are intrinsically disordered and that this structural 
property could help recognition and transport by the secretion systems [43]. In order to facilitate the 
crystallization process, we removed the 139 N-terminal residues corresponding to the predicted 
translocation signal of SlrP [41]. Because T3SS signal sequences are reported as non-cleaved in vivo [44], 
we verified that the truncated His-tagged recombinant protein restricted to the LRR and NEL domains of 
SlrP (residues 140-765, 73kDa) kept its ability to bind Trx1 (Figure S1). Pull-down experiments 
confirmed that the truncated form of SlrP could be used for co-crystallization experiments with Trx1.  
We obtained crystals containing two SlrP and two Trx1 molecules per asymmetric unit. Trx1 displays 
the well-characterized α/β fold very similar to the reduced form of free Trx1 (PDB ID 1ERT) [45], with 
an rmsd distance of about 0.67Å for 105 Cα atoms aligned between the two subunits. The two SlrP 
subunits present the same overall structure (Figure 1A) with an rmsd distance of 1.1Å for 589 Cα atoms 
aligned. The LRR domain of SlrP (residues 147-450) is N-capped by two antiparallel α-helices, α1 and α2, 
and contains 13 LRR motifs (Figure 1B). The loop of LRR-11 contains a short extension. The loop of 
LRR-12 is replaced by a capping α-helix, α3, while the loop of LRR-13 forms a linker of 15 residues 
(451-464) between the LRR domain and the fully α-helical NEL domain (helices αA to αN, residues 465-
765). The later displays the characteristic globular core followed by a protruding helix bundle (Figure 1A). 
In both copies of the NEL domain there was no visible electron density for loop αM-αN (residues 709-
728) of the C-terminal helix bundle. In contrast, the loop linking the LRR and NEL domains that was 
disordered in the published apo structures of IpaH3 [21] and SspH2 [22] is clearly defined in the Trx1 
bound SlrP structure. The catalytic loop carrying the conserved C546XD548 motif [24] is exposed to the 
solvent and accessible to the E2-Ub conjugate.  
 
The SlrP/Trx1 complex forms a heterotetramer 
Two head-to-tail SlrP subunits are bridged by two Trx1 subunits, resulting in an unexpected 
heterotetramer (Figure 2A). The latter forms a stable complex characterized by a total buried solvent-
accessible surface area of 5208.2Å2 and a solvation free energy gain ΔiG of -21.3kcal/mol.  
The two bound Trx1 subunits make only few contacts with each other, involving a small interface 
area of 125.7Å2 (ΔiG= -0.3 kcal/mol) at their C-terminal helices (Figure 2A). This Trx1-Trx1interaction 
mode is completely different from that observed in the inactive oxidized Trx1 dimer (PDB ID 1AIU) in 
which monomers are disulfide-linked through Cys73 from each subunit [45]. Similarly, the two SlrP 
subunits display a very small interface area of 96.1Å2 (ΔiG= +0.3kcal/mol) involving a small loop located 
between the LRR-11 and LRR-12 motifs (residues P415-Q416-P417) (Figure 2B). The contacts between SlrP 
and Trx1 subunits are slightly more important. Each SlrP molecule interacts with both Trx1 subunits. The 
concave surface of the LRR domain forms the so-called type-I binding site (Figure 2C) characterized by 
an average interface area of 729.2Å2 and a solvation energy gain of ΔiG= -2.6 kcal/mol. These contacts 
mainly involve basic residues from the SlrP LRR domain and the acidic region Glu56-Asp61 from Trx1. 
The linker loop of SlrP (residues 451-464) forms a type-II binding site (Figure 2D) characterised by an 
average interface area of about the same size (655.5 Å2) but associated with a larger solvation free energy 
gain of ΔiG= -10.9 kcal/mol. These contacts mainly involve residues from the linker region of SlrP and 
loops 68-74 and 88-92 from Trx1. Analysis of the heterotetramer interfaces using PDBePISA suggested 
that only this type-II Slrp/Trx1 interface could form stable assemblies in solution.  
Detailed analysis of this type-II interface (Figure 2D) suggested that mutating into glutamate the SlrP 
hydrophobic residues Val459 and Val461 or the Trx1 residue Gly91 could disrupt the complex. This 
hypothesis was experimentally tested using the yeast two-hybrid system. As seen in Figure 3, whereas 
wild-type SlrP and Trx1 were able to interact, mutant SlrP-V459E/V461E was unable to bind Trx1, and 
Biochemical Journal Immediate Publication. Published on 03 Sep 2014 as manuscript BJ20140587
TH
IS
 IS
 N
O
T 
TH
E 
VE
RS
IO
N 
O
F 
RE
CO
RD
 - 
se
e 
do
i:1
0.
10
42
/B
J2
01
40
58
7
Ac
c
pte
d M
a
us
cri
pt
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2014 The Authors Journal compilation © 2014 Biochemical Society
  
 
8
mutant Trx1-G91E was unable to bind SlrP. These results confirm the importance of the type-II SlrP/Trx1 
interface for the interaction of the two proteins. 
The question of the biological relevance of the heterotetramer observed in the crystal, with formation 
of the type-I SlrP/Trx1 interface, was assessed using SEC-MALLS analysis (Figure 4). SlrP was eluted in 
two peaks corresponding to a monomer and a dimer, respectively. Trx1 was eluted as a monomer. An 
equimolar mix of SlrP and Trx1 was eluted in two peaks corresponding to a 1:1 complex and a 2:2 
complex. This result demonstrates that two forms of SlrP, monomeric and dimeric, co-exist in solution 
and that both of them bind Trx1.  
 
Identification of a Trx1 ubiquitination site 
The catalytic loop of the SlrP subunits does not directly interact with a bound substrate molecule, and 
none of the 12 lysines contained in Trx1 was clearly orientated toward the active site of the NEL domain, 
suggesting that the observed heterotetramer could correspond to an intermediate in the ubiquitination 
mechanism.  
Three Trx1 lysine residues (Lys8, Lys36 and Lys94) exposed at the surface of the molecule (Figure 
5A) were considered as potential ubiquitination sites and mutated into alanine. The ability of SlrP to 
ubiquitinate these mutant proteins was tested in vitro in the presence of recombinant human E1 ubiquitin-
activating enzyme and E2 ubiquitin-conjugating enzyme. The ubiquitination profiles of Trx1-K8A and 
Trx1-K36A mutants were similar to the wt-Trx1 profile. Interestingly, Trx1-K94A and the triple mutant 
protein Trx1-K8A/K36A/K94A displayed a strongly reduced ubiquitination profile (Figure 5B). These 
results suggested that Lys94 is one of the main target sites for Trx1 SlrP-dependent ubiquitination. 
However, the ubiquitination profiles of Trx1-K94A and of the triple Trx1 mutant still displayed some 
slight bands in the Western blot analysis and it cannot be excluded that other lysine residues could also be 
ubiquitinated. The Trx1 residue Lys94 and the SlrP catalytic Cys546 are spaced about 40Å apart (Figure 
5A). The SlrP catalytic loop is exposed to the solvent, suggesting that it is compatible with the binding of 
the E2-Ub complex. However, an important reorientation of the NEL domain will be required after 
ubiquitin binding to allow Lys94 to exert a nucleophilic attack on the intermediate Cys546-ubiquitin 
thioester bond. Once the ubiquitin molecule transferred to Trx1, this post-translational modification 
would most probably impair the conserved C32GPC35 catalytic motif, located close to Lys36 on the same 
face of Trx1 than the Lys94 ubiquitination site (Figure 5A), to interact with the Trx1 substrates. This 
would explain the observed SlrP-dependent inhibition of the Trx1 reducing activity [24]. Interestingly, 
other post-translational modifications including glutathionylation, thiol-oxidation, and S-nitrosylation, at 
the non-active cysteines have already been shown to importantly contribute to the regulation of Trx1 [46]. 
 
DISCUSSION 
 
Previous studies demonstrated that removal of the LRR domain of SlrP (residues 1-457) resulted in 
dramatic increase of its ubiquitin E3 ligase activity [22]. These results suggest that the LRR domain, 
known as a versatile structural framework for protein-protein interaction [47], is not implicated in 
substrate binding but is rather involved in the regulation of the adjacent NEL catalytic domain [14].  
The structure of the SlrP/Trx1 complex presented in this paper demonstrates the linker region 
between the NEL and LRR domains plays an essential role in substrate binding. Comparison of the 
SlrP/Trx1 complex with the apo structures of the NEL effectors IpaH3 from Shigella (PDB ID 3CVR) 
[21] and SspH2 from Salmonella (PDB ID 3G06) [22] shed light on the molecular mechanism of these 
ubiquitin E3 ligases.  
Holo SlrP displays the same open conformation as the apo structure of IpaH3 (Figure 6A). An 
internal LRR-NEL interface area of about 711.2Å2 (∆iG=-3.4 kcal/mol) stabilizes the relative orientation 
of the LRR and NEL domains. As observed in IpaH3 [21], a conserved phenylalanine residue from loop 
αG-αH in the NEL domain, corresponding to SlrP Phe604 (Figure S2), is buried into a hydrophobic 
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pocket formed by the -helix capping the C-terminus of the LRR-domain (SlrP helix α3) and the convex 
side of this LRR domain (Figure 6B).  
In the SspH2 structure (PDB ID 3G06) [22], the SspH2 residue Leu638 corresponding to SlrP Phe604 
(Figure S2) is buried in a hydrophobic pocket formed by the other face of the -helix C-capping the LLR 
domain (SspH2 helix α4 = SlrP helix α3) and the N-terminal extremity of the linker loop. In this closed 
conformation, the NEL domain is turned toward the concave face of the LRR domain and the catalytic 
cysteine is buried in this interface (Figure 6C). Interestingly, it has been shown that the conservative Leu 
to Phe mutation of the essential hydrophobic residue from loop αG-αH had no effect on the LRR-
dependent inhibition [23]. Furthermore, the hydrophobic residues (Ile479, Phe481 and Met483) from the 
SspH2 linker region that have been shown to stabilize this conformation are conserved in SlrP (Val449, 
Phe451 and Met453, Figure S2). This suggests that SlrP could adopt the SspH2 open conformation. 
However, this conformation is incompatible with the Trx1 type-II binding mode (Figure 6D).  
Together with the observation of an equilibrium between a monomeric and a dimeric form of apo 
SlrP in solution (Figure 4A), these data further suggest that apo SlrP could fluctuate between two 
monomeric conformations:  (i) an auto-inhibited closed conformation that sequesters the catalytic cysteine 
and masks the substrate-binding site, and (ii) an open conformation compatible with substrate binding and 
interaction with the E2-Ub complex. Formation of the Ub-E3 thioester bond [23] could induce the release 
of the inhibitory interaction between the NEL residue Phe604 and the convex side of the LRR domain, 
thus allowing a conformational change compatible with the transfer of the ubiquitin molecule to Trx1 
Lys94. This step could involve internal reorganization of the NEL domain that has been shown to contain 
three subdomains [19]. The catalytic cysteine is indeed situated in the loop connecting the N-terminal 
lobe to the middle lobe. Its thioesterification with ubiquitin could thus modify the relative orientation of 
these two subdomains and disrupt the autoinhibiting interaction between the LRR domain and the 
hydrophobic NEL residue Phe604 from loop αG-αH located in the middle lobe. 
We propose that the apo SlrP dimer observed in solution (Figure 4A) could form between two 
subunits in the closed conformation. In the crystallized heterotetramer, the contacts between the two SlrP 
subunits in the open conformation are indeed too weak (Figure 2B) to form a stable assembly in the 
absence of bound Trx1. The head-to-tail dimerization mode observed in the heterotretramer could be 
conserved and the contacts made by the two Trx1 subunits could be made by the NEL domains that 
superimpose in the closed conformation with the Trx1 molecules bound to the open conformation (Figure 
6D). The 2:2 SlrP/Trx1 complex observed in solution (Figure 4C) could thus form either by head-to-tail 
dimerization of two type-II SlrP/Trx1 1:1 complexes or by direct substrate binding to the apo SlrP dimer.   
Finally, the Trx1 ubiquitinatable residue Lys94 is buried in the resulting type-I interface, suggesting 
that Trx1 ubiquitination would anyway require dissociation of the heterotetramer into two type-II 
SlrP/Trx1 complexes. The conformational change of induced upon thioesterification of the catalystic 
Cys546 would thus most probably induce dissociation of the two type-II SlrP/Trx1 complexes.  
This proposed molecular mechanism (Figure 7) could apply to other members of the NEL family. 
However, multiple sequence alignments performed with distant homologues of the LRR-NEL family of 
T3SS effectors (Figure S2) demonstrated that the P415-Q416-P417 motif forming the small SlrP-SlrP contact 
region of the heterotetramer corresponds to a small extension restricted to SlrP members of the family. 
This suggests that other LRR-NEL effectors could not form dimers. SlrP dimerization could be required 
to stabilize binding of the small molecule substrate Trx1, which presents only a small interface area. 
Recently, the structural analysis of the LRR domain of SspH1 in complex with the small HR1B domain of 
PKN1 (PDB ID 4NKG) [48] suggested a totally distinct substrate-binding mode. However only a small 
domain of the protein substrate (residues 122-199 from 942) is present in this structure and we cannot 
exclude that binding of full-length PKN1 to full-length SspH1 would involve other parts of the proteins, 
and in particular the linker region as observed in the SlrP/Trx1 complex. Another structure of a LRR-NEL 
effector in complex with its full-length protein substrate will be required to elucidate if the substrate-
binding mode is specific to each family member.  
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FIGURE LEGENDS 
 
 
Figure 1: Structure of SlrP 
(A) Overall 3D structure of the SlrP subunit. The polypeptide chain is shown as cartoon coloured from 
blue (N-ter) to red (C-ter). The secondary structure elements are labelled as well as the LRR-domain 
(residues 147-450), the linker region (residues 451-464) and the NEL-domain (residues (465-765). (B) 
Sequence alignment of the 13 LRR repeats. LRR-1 (residues 180-199), LRR-2 (residues 200-220), LRR-3 
(residues 221-242), LRR-4 (residues 243-262), LRR-5 (residues 263-284), LRR-6 (residues 285-305), 
LRR-7 (residues 306-325), LRR-8 (residues 326-346), LRR-9 (residues 347-368), LRR-10 (residues 369-
389) and LRR-11 (residues 390-417) are aligned with the positions of the conserved -strand displayed at 
the top of the alignment. The unconventional LRR-12 (residues 418-445) and LRR-13 (residues 446-464) 
are shown separately with the position of the capping helix α3 and the linker region highlighted above the 
corresponding sequence. 
 
Figure 2: The SlrP/Trx1 heterotetramer 
(A) Crystal structure of the head to tail SlrP/Trx1 heterotetramer.  Each subunit is shown as cartoon in the 
envelope corresponding to the surface of the complex. The SlrP molecules are coloured by spectrum from 
blue to red while the Trx1 molecules are coloured gray and beige, respectively. (B) The SlrP/SlrP 
interface. Close view of the contact region between the two SlrP subunits. Residues P415-Q416-P417 from 
the LRR-11 extension are highlighted. (C) Type-I SlrP/Trx1 interface. Close view of the contact region 
between the LRR domain of SlrP and one molecule of Trx1. Residues directly involved in the contact are 
highlighted. (D) Type-II SlrP/Trx1 interface. Close view of the contact region between the linker loop of 
SlrP and the second molecule of Trx1. Residues directly involved in the contact are highlighted. SlrP 
residues Val459 and Val461 as well as Trx1 Gly91 have been mutated into E to assess the biological 
relevance of this interaction mode. 
 
Figure 3: Disruption of binding between SlrP and Trx1 by point mutations in the type-II SlrP/Trx1 
interface.  
The yeast two-hybrid system was used to test the interaction between SlrP, Trx1 and their mutants. 
Diploids were obtained by conjugation between yeast strain Y2HGold containing derivatives of pGBKT7, 
and yeast strain Y187 containing derivatives of pGADT7, as indicated. The pGBKT7 vector expresses 
proteins fused to the Gal4 DNA-binding domain, whereas pGADT7 expresses proteins fused to the Gal4 
activation domain. The interaction between the two hybrid proteins is shown by growth in the absence of 
histidine and adenine. Empty vectors (-) were used as negative controls. 
 
Figure 4: SEC-MALLS analysis of the SlrP/Trx1 interaction. 
 (A) An SlrP sample at 1.2 mg/ml (16 µM) eluted from the column in two peaks corresponding to a 
monomer (79 kDa) and a dimer (149 kDa), respectively. (B) A Trx1 sample at 1.0 mg/ml (83 µM) eluted 
from the column as a monomer (12 kDa). (C) An equimolar mix of SlrP and Trx1 eluted from the column 
in two peaks corresponding to a 1:1 complex (86 kDa) and a 2:2 complex (172 kDa), respectively. 
 
Figure 5: Trx1 ubiquitination  
(A) Localisation of the three Trx1 mutated residues Lys8, Lys36 and Lys94. The distance between SlrP 
catalytic Cys546 and Trx1 ubiquitinated Lys94 is indicated.  (B) SlrP-dependent ubiquitination assays 
using the Trx1-K8A, -K36A, -K94A and -K8A/K36A/K94A mutants. Reactions performed in the 
presence of HA-ubiquitin, E1, E2, GST-SlrP (SlrP), and GST-Trx1 (Trx), as indicated, were 
immunoprecipitated with anti-Trx antibodies. The precipitates were resolved in 10% SDS-PAGE and 
analyzed by immunoblot with anti-HA (upper panel) or anti-Trx (lower panel) antibodies. Putative 
ubiquitinated forms of Trx1 are indicated (Trx-Ub). 
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Figure 6: Comparison with other LRR-NEL effectors 
(A) Superimposition of the NEL domains. One SlrP subunit of the SlrP/Trx1 complex is shown as cartoon 
coloured in yellow. Apo IpaH3 (PDB ID 3CVR) is shown in magenta and apo SspH2 (PDB ID 3G06) in 
cyan. (B) Close view of the conserved NEL-LRR contacts in the open conformation observed in the 
SlrP/Trx1 complex. SlrP is shown as cartoon coloured spectrum with the electrostatic surface of the LRR 
domain in transparency. The NEL residue Phe604 from loop αG-αH is buried in a hydrophobic pocket on 
the convex side of the LRR domain. The SlrP catalytic cysteine Cys546 is highlighted.   (C) Close view 
of the NEL-LRR contacts in the closed conformation observed in the SspH2 structure (PDB ID 3G06). 
SspH2 is shown as cartoon coloured spectrum with the electrostatic surface of the LRR domain in 
transparency. SspH2 residue Leu638 from loop αG-αH (equivalent to SlrP residue Phe604) is buried in a 
hydrophobic pocket on the concace side of the LRR domain.  The SspH2 catalytic cysteine is highlighted. 
(D) Superimposition of the LRR domain of SspH2 with a SlrP/Trx1 heterodimer. The NEL domain of apo 
SspH2 (PDB ID 3G06, in cyan) occupies the same position as the Trx1 molecule (in beige) bound in the 
type-I binding site of SlrP (in yellow).  
 
Figure 7: Schematic representation of the proposed molecular mechanism. The equilibrium between 
a monomeric and a dimeric conformation for is inferred from the SEC-MALLS analysis. The equilibrium 
between the open and closed monomeric conformation of apo SlrP is inferred from the comparison with 
the other members of the family. The 2:2 SlrP/Trx1 complex corresponds to the structure presented in this 
article. The 1:1 complex conformation is based on the type-II SlrP/Trx1 interaction mode. The different 
steps allowing thioesterification of the SlrP catalytic C546 by the human E2-Ub complex are still unclear. 
But dissociation of the 2:2 complex and conformational change of the of the 1:1 complex required for 
ubiquitin transfer from SlrP Cys546 to Trx1 Lys94 are represented.  
 
 
 
 
SUPPORTING INFORMATION 
 
Table S1 : Oligonucleotides used in this study 
 
Figure S1: Pull-down experiments using SlrP fragments and GST-Trx1 
SlrP fragments containing amino acids 1-140 (SlrP1) and 140-765 (SlrP2) were produced in E. coli 
M15/pREP4 as N-terminal 6His fusions (input). Bacterial extracts were incubated with either GST alone 
or GST-Trx1 (GST-Trx) immobilized on glutathione-agarose beads. After washing, the bound proteins 
were analyzed by immunoblot using anti-6His antibodies. 
 
Figure S2: Multiple sequence alignment of NEL effectors  
The sequence of SlrP (UniProt KB entry D0ZRB2) has been aligned using ClustalW with homologues 
found by similarity searches using BLAST. The first part of the alignment corresponding to the first ten 
LRR repeats is not shown. The secondary structure elements of SlrP, SspH2 (3G06) and IpaH3 (3CVR) 
have been added at the top of the alignment using ESPript. 
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Table 1: X-ray data processing and refinement statistics. 
Data processing statistics Native data set SAD data set (SeMet) 
Space group  P212121 P212121 
Unit-cell parameters (Å) a=106.3; b=134.8; c=154.6 a=106.7; b=135.0; c=153.9 
Unit-cell angles (°) α=90°; β =90°; γ=90° α=90°; β =90°; γ=90° 
Resolution range (Å)  45.0 - 3.3 (3.49 – 3.29)* 50.0 - 3.6 (3.84 – 3.63)* 
No. of unique reflections 34042 (5402) 48 641 (7789) 
Completeness (%) 99.4 (98.1) 99.8 (98.8) 
Redundancy 4.4 (4.6) 7.8 (7.7) 
Mean I/ (I) 16.84 (2.83) 15.77 (3.48) 
Rmeas (%)† 5.6 (69.9) 9.8 (62.9) 
Refinement statistics Against native data set 
Resolution range 44.0 - 3.3 (3.4 – 3.3) 
No. of molecules/a.u. 4 
Rwork (%)‡ 27.17 (43.54) 
Rfree (%)§ 30.84 (47.99) 
Ramachandran  
      Favoured (%) 91.4 
      Disallowed (%) 0.9 
R.M.S.D.  
     Bond lengths (Å) 0.003 
     Bond angles (°) 0.785 
     Dihedral angle (°) 11.736 
     Chirality 0.049 
     Planarity 0.005 
Mean B value (Å2) 118.53 
* Numbers in parentheses represent values in the highest resolution shell. 
† Rmeas = Shkl [N/N-1]
1/2Si |Ii(hkl) - <I(hkl)>| / ShklSi Ii(hkl) where N is the multiplicity of a given 
reflection, Ii(hkl) is the integrated intensity of a given reflection and <I(hkl)> is the mean intensity of 
multiple corresponding symmetry-related reflections. 
‡ Rwork = S ||Fobs| - |Fcalc|| / S |Fobs|, where |Fobs| and |Fcalc| are the observed and calculated structure 
factor amplitudes respectively. 
§ Rfree is the same as Rwork but calculated with a 5% subset of all reflections that was never used in 
crystallographic refinement. 
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